My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

51.38 +51.37 (+1007350.98%)

Streaming Delayed Price Updated: 9:33 AM EDT, Jun 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

37 38 Next >

The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate ↗

July 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma

July 06, 2022

From Genentech

Via Business Wire

Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug ↗

July 01, 2022

The study was in 26 patients with chronic hives that don't respond to antihistamines.

Via Investor's Business Daily

The OTC Markets' Most-Active Securities Embrace International Operators As Volatility Envelops Markets In May ↗

June 17, 2022

Reflecting the world’s uncertainty about the U.S. economy, the market’s major indices saw incredible volatility in May.

Via Benzinga

Why Mereo BioPharma Shares Are Jumping Today ↗

June 17, 2022

Via Benzinga

Roche's Alzheimer's Failures Keep Piling Up; Can The Stock Recover? ↗

June 16, 2022

Roche hoped to prevent Alzheimer's disease in patients with a genetic defect.

Via Investor's Business Daily

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK ↗

June 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients ↗

June 16, 2022

Via Benzinga

Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

June 16, 2022

From Genentech

Via Business Wire

5 Cash-Cow Stocks to Buy for a Turbulent Market ↗

June 10, 2022

These are five of the best cash-cow stocks and ETFs to buy that could help grow your investment portfolio in the second half of 2022

Via InvestorPlace

Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting

June 10, 2022

From Genentech

Via Business Wire

The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data ↗

June 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients ↗

June 06, 2022

Via Benzinga

Diagnostic Companies Focus On Monkeypox Tests Following Outbreak; Experts Do Not Count It As Next COVID Yet ↗

June 03, 2022

Diagnostic companies aggressively developed tests for monkeypox as governments struggle to trace the world's first major viral infection outbreak beyond Africa,

Via Benzinga

FDA Approves Genentech’s Evrysdi (risdiplam) for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)

May 31, 2022

From Genentech

Via Business Wire

New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma

May 26, 2022

From Genentech

Via Business Wire

One-Trick Pony Boan Biotech Files for Hong Kong IPO Into Tough Market ↗

May 24, 2022

Key Takeaways: Boan Biotechnology sells only one product so far and is facing stiff competition from other similar drugs Luye Pharma bought Boan in 2020 and is taking it public...

Via Benzinga

Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare

May 24, 2022

From Genentech

Via Business Wire

Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer ↗

May 23, 2022

Via Benzinga

Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients ↗

May 17, 2022

Via Benzinga

Current Report: Roche Holding ↗

May 16, 2022

Roche’s price per share was $39.75 as of Friday's market close. One year ago its price was $42.20.

Via Talk Markets

The OTC Markets' Most Active Securities Welcomes New Names And Experiences A Reshuffle In April ↗

May 13, 2022

Photo by Becca on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. First-quarter 2022 market...

Via Benzinga

Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others ↗

May 11, 2022

Roche isn't the only company working on an anti-TIGIT molecule.

Via Investor's Business Daily

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine ↗

May 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer ↗

May 11, 2022

Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung...

Via Benzinga

Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

May 11, 2022

From Genentech

Via Business Wire

Market Selloff ↗

May 10, 2022

In a U.S. market selloff, the strong performance of mostly foreign issues was impressive.

Via Talk Markets

Roche Releases More Evrysdi Data For Very Young Infants With SMA ↗

April 29, 2022

Via Benzinga

New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)

April 29, 2022

From Genentech

Via Business Wire

Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook ↗

April 26, 2022

Via Benzinga

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.